Now showing items 1-20 of 139

    • 18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. 

      Berrevoets, MAH; Kouijzer, IJE; Aarntzen, EHJG; Janssen, MJR; De Geus-Oei, L-F; Wertheim, HFL; Kullberg, B-J; Oever, JT; Oyen, WJG; Bleeker-Rovers, CP (2017-09)
      Metastatic infection is an important complication of Staphylococcus aureus bacteremia (SAB). Early diagnosis of metastatic infection is crucial, because specific treatment is required. However, metastatic infection can be ...
    • Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. 

      Desar, IME; Braam, PM; Kaal, SEJ; Gerritsen, WR; Oyen, WJG; van der Graaf, WTA (2016-12)
    • Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG. 

      Grünwald, V; Litière, S; Young, R; Messiou, C; Lia, M; Wardelmann, E; van der Graaf, W; Gronchi, A; Judson, I; EORTC STBSG (2016-09)
      Anthracycline-based chemotherapy remains the mainstay of first-line treatment in metastatic or advanced soft-tissue sarcoma (STS). Age, performance status, tumour histology and tumour grade are recognised prognostic factors; ...
    • Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. 

      Schöffski, P; Wozniak, A; Stacchiotti, S; Rutkowski, P; Blay, J-Y; Lindner, LH; Strauss, SJ; Anthoney, A; Duffaud, F; Richter, S; Grünwald, V; Leahy, MG; Reichardt, P; Sufliarsky, J; van der Graaf, WT; Sciot, R; Debiec-Rychter, M; van Cann, T; Marréaud, S; Lia, M; Raveloarivahy, T; Collette, L; Bauer, S (2017-12)
      Background:Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the ...
    • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 

      Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, CG; Marples, M; Danson, SJ; Marshall, E; Houston, SJ; Board, RE; Waterston, AM; Nobes, JP; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, PM; Ottensmeier, CH; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, EO; Harman, C; Weiss, M; Myers, KA; Chhabra, A; Rodwell, SH; Dunn, JA; Middleton, MR; AVAST-M Investigators (2018-08)
      Background:Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ...
    • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. 

      Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandalà, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM (2017-11)
      BACKGROUND:Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ...
    • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. 

      Weber, J; Mandala, M; Del Vecchio, M; Gogas, HJ; Arance, AM; Cowey, CL; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, J-J; Butler, MO; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, RR; Smylie, M; Meyer, N; Mortier, L; Atkins, MB; Long, GV; Bhatia, S; Lebbé, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, TM; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, PA; CheckMate 238 Collaborators (2017-11)
      BACKGROUND:Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma ...
    • Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. 

      Husson, O; Prins, JB; Kaal, SEJ; Oerlemans, S; Stevens, WB; Zebrack, B; van der Graaf, WTA; van de Poll-Franse, LV (2017-02)
      Trying to simultaneously achieve developmental milestones and cope with a life-threatening disease may place adolescents and young adults (AYAs) at risk for impaired health-related quality of life (HRQoL) later in life. ...
    • Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. 

      Muro, K; Cho, JY; Bodoky, G; Goswami, C; Chao, Y; Dos Santos, LV; Shimada, Y; Topuzov, E; Van Cutsem, E; Tabernero, J; Zalcberg, J; Chau, I; Cascinu, S; Cheng, R; Hsu, Y; Emig, M; Orlando, M; Fuchs, C (2018-04)
      REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess ...
    • Age-related sarcoma patient experience: results from a national survey in England. 

      Younger, E; Husson, O; Bennister, L; Whelan, J; Wilson, R; Roast, A; Jones, RL; van der Graaf, WT (2018-10-17)
      BACKGROUND:Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers. Consequently, Sarcoma ...
    • Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. 

      Ostrom, QT; Kinnersley, B; Armstrong, G; Rice, T; Chen, Y; Wiencke, JK; McCoy, LS; Hansen, HM; Amos, CI; Bernstein, JL; Claus, EB; Eckel-Passow, JE; Il'yasova, D; Johansen, C; Lachance, DH; Lai, RK; Merrell, RT; Olson, SH; Sadetzki, S; Schildkraut, JM; Shete, S; Rubin, JB; Andersson, U; Rajaraman, P; Chanock, SJ; Linet, MS; Wang, Z; Yeager, M; GliomaScan consortium; Houlston, RS; Jenkins, RB; Wrensch, MR; Melin, B; Bondy, ML; Barnholtz-Sloan, JS (2018-11)
      Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM increases with age, and younger age-at-diagnosis is significantly associated with improved prognosis. While the relationship ...
    • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. 

      Frezza, AM; Jones, RL; Lo Vullo, S; Asano, N; Lucibello, F; Ben-Ami, E; Ratan, R; Teterycz, P; Boye, K; Brahmi, M; Palmerini, E; Fedenko, A; Vincenzi, B; Brunello, A; Desar, IME; Benjamin, RS; Blay, JY; Broto, JM; Casali, PG; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Mir, O; Rutkowski, P; Wagner, AJ; Anurova, O; Collini, P; Dei Tos, AP; Flucke, U; Hornick, JL; Lobmaier, I; Philippe, T; Picci, P; Ranchere, D; Renne, SL; Sbaraglia, M; Thway, K; Wagrodzki, M; Wang, W-L; Yoshida, A; Mariani, L; Kawai, A; Stacchiotti, S (2018-09-13)
      Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the ...
    • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 

      Khankari, NK; Shu, X-O; Wen, W; Kraft, P; Lindström, S; Peters, U; Schildkraut, J; Schumacher, F; Bofetta, P; Risch, A; Bickeböller, H; Amos, CI; Easton, D; Eeles, RA; Eeles, RA; Gruber, SB; Haiman, CA; Hunter, DJ; Chanock, SJ; Pierce, BL; Zheng, W; Colorectal Transdisciplinary Study (CORECT); Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE); Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE); Transdisciplinary Research in Cancer of the Lung (TRICL) (2016-09-06)
      BACKGROUND:Observational studies examining associations between adult height and risk of colorectal, prostate, and lung cancers have generated mixed results. We conducted meta-analyses using data from prospective cohort ...
    • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. 

      Premenopausal Breast Cancer Collaborative Group; Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Braaten, T; Chen, Y; Connor, AE; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Linet, MS; Ma, H; Masala, G; Merritt, MA; Milne, RL; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Yuan, J-M; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2018-11-08)
      Importance:The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND:Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12)
      Importance:Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background:Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. 

      Ladenstein, R; Pötschger, U; Pearson, ADJ; Brock, P; Luksch, R; Castel, V; Yaniv, I; Papadakis, V; Laureys, G; Malis, J; Balwierz, W; Ruud, E; Kogner, P; Schroeder, H; de Lacerda, AF; Beck-Popovic, M; Bician, P; Garami, M; Trahair, T; Canete, A; Ambros, PF; Holmes, K; Gaze, M; Schreier, G; Garaventa, A; Vassal, G; Michon, J; Valteau-Couanet, D; SIOP Europe Neuroblastoma Group (SIOPEN) (2017-04)
      High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. We aimed ...